


STATE OF CONNECTICUT

DEPARTMENT OF PUBLIC HEALTH

Raul Pino, M.D., M.P.H.
Commissioner



Dannel P. Malloy
Governor
Nancy Wyman
Lt. Governor

Immunization Program

PLEASE COPY THIS FOR ALL HEALTH CARE PROVIDERS IN YOUR PRACTICE

TO: Health Care Providers

**FROM: Mick Bolduc-Vaccine Coordinator
Connecticut Vaccine Program (CVP)**

A handwritten signature in black ink, appearing to read "Mick Bolduc".

DATE: June 28, 2017

SUBJECT: Updated serogroup B Meningococcal Vaccine Recommendations

The primary purpose of this communication is to inform you of new recommendations for serogroup B Meningococcal Vaccine.

Serogroup B Meningococcal vaccine

Two serogroup B meningococcal vaccines (MenB) are currently licensed for use in persons aged 10–25 years in the United States. The two vaccines are Trumenba® (Pfizer) and Bexsero® (GlaxoSmithKline). In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended use of MenB vaccines among certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease, and in June 2015, ACIP recommended that adolescents and young adults aged 16–23 years may be vaccinated with MenB vaccines to provide short-term protection against most strains of serogroup B meningococcal disease. Consistent with the original Food and Drug Administration (FDA) licensure for the two available MenB vaccines, ACIP recommended either a 3-dose series of Trumenba® or a 2-dose series of Bexsero®. **In April 2016, changes to the dosage and administration of Trumenba® were approved by FDA: for persons at increased risk for meningococcal disease and for use during serogroup B disease outbreaks, ACIP recommends a 3 dose series be administered at 0, 1-2 months and 6 months; for healthy adolescents who are not at increased risk for meningococcal disease, ACIP recommends a 2 dose series at 0, and 6 months.** Recommendations regarding use of Bexsero® are unchanged.



Phone: (860) 509-7929 • Fax: (860) 509-7945
410 Capitol Avenue, P.O. Box 340308
Hartford, Connecticut 06134-0308
www.ct.gov/dph

Affirmative Action/Equal Opportunity Employer



Either MenB vaccine can be used when indicated; ACIP does not state a product preference. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses in a series.

As always, if you have any questions, please feel free to contact me at (860) 509-7940.